Published online Jun 18, 2021. doi: 10.5312/wjo.v12.i6.395
Peer-review started: January 3, 2021
First decision: March 1, 2021
Revised: March 22, 2021
Accepted: May 20, 2021
Article in press: May 20, 2021
Published online: June 18, 2021
There is a paucity of data evaluating patients with dermatomyositis (DM) and polymyositis (PM) undergoing total hip arthroplasty (THA).
To compare and contrast the outcomes of patients undergoing THA with DM and PM vs a matched control without inflammatory arthropathies.
To elucidate whether patients with DM and PM have increased risk of complications and greater 90-d costs when undergoing THA compared to controls.
A retrospective case control was performed based on the medicare data.
Patients with DM and PM had increased rates of pneumonia [odds ratio (OR) 1.45, P < 0.001] and pulmonary embolism (OR 1.46, P = 0.035) and decreased hematoma risks (OR 0.58, P = 0.00). 90-d costs were on average $1411 greater for those with idiopathic inflammatory myopathies (IIM) yet not significantly different (P = 0.034).
Patients with IIM have an increased 90-d rate of pneumonia and pulmonary embolism concomitant with a decreased hematoma rate consistent with their pro-coagulatory state.
It is important to evaluate deep vein thrombose prophylaxis and respiratory status in those undergoing THA with DM or PM.